COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database


Abstract

Vaccination against viruses has rarely been associated with Guillain-Barré syndrome (GBS). An association with the COVID-19 vaccine is unknown. We performed a population-based study of National Health Service (NHS) data in England and a multicentre surveillance study from UK hospitals, to investigate the relationship between COVID-19 vaccination and GBS.

Firstly, we present a retrospective analysis of every GBS patient in England in the National Immunoglobulin Database (NID) linked with their COVID-19 vaccination data. Cases of GBS identified in the National Immunoglobulin Database (NID) from 8 December 2021 to 8 July 2021 were linked to data from the National Immunisation Management System (NIMS) in England to identify exposure to a COVID-19 vaccine. For the NID/NIMS linked dataset, GBS cases temporally associated with vaccination within a 6-week risk window of any COVID-19 vaccine were identified. Secondly, we prospectively collected incident UK GBS cases from 1 January 2021 to 7 November 2021 in a separate UK multicentre surveillance database, regardless of vaccine exposure, with vaccine timings and GBS phenotypic data. For this multicentre UK surveillance dataset, we explored phenotypes of reported GBS cases to identify features of COVID-19 vaccine-associated GBS.

996 GBS cases were recorded in the NID from January to October 2021. A spike of GBS cases above the 2016-2020 average occurred in March-April 2021. In England, among all cases of GBS, 198 occurred within 6 weeks of the first-dose COVID-19 vaccination (0.618 cases per 100,000 vaccinations, 176 ChAdOx1 nCoV-19 (AstraZeneca), 21 tozinameran (Pfizer), 1 mRNA-1273 (Moderna)). The excess of GBS occurs with a peak at 24 days; first-doses of ChAdOx1 nCoV-19 accounted for the excess. No excess was seen for second-dose vaccination. The absolute number of excess GBS cases was between 98-140 cases for first-dose ChAdOx1 nCoV-19 vaccination from January-July 2021. First-dose tozinameran and second-dose of any vaccination showed no excess GBS risk. 121 patients were reported in the separate multicentre surveillance dataset with no
phenotypic or demographic differences identified between vaccinated and non-vaccinated GBS cases.

Data from the linked NID/NIMS dataset suggest that first-dose ChAdOx1 nCoV-19 vaccination is associated with an excess GBS risk of 0.576 (95% CI 0.481-0.691) cases per 100,000 doses. However, further data reported from a multicentre surveillance dataset suggest that no specific clinical features, including facial weakness, are associated with vaccination-related GBS compared to non-vaccinated cases. The pathogenic cause of the ChAdOx1 nCoV-19 specific first dose link warrants further study.

**Author affiliations:**

1 MRC Centre for Neuromuscular Diseases, National Hospital of Neurology and Neurosurgery, Queen Square, University College London Hospitals NHS Foundation Trust, London, UK.

2 Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester, UK.

3 Medicines and Healthcare products Regulatory Agency, UK

4 NHS England & Improvement (NHSEI), National Health Service, UK

5 Medical Data Solutions and Services (MDSAS) Ltd, data platform provider for the National Immunoglobulin Database

6 NHS Arden and Greater East Midlands (GEM) Commissioning Support Unit (CSU), UK

7 Institute of Neurology, University College London, London, UK

Correspondence to: Michael P. Lunn

MRC Centre for Neuromuscular Diseases, National Hospital of Neurology and Neurosurgery, Queen Square, University College London Hospitals NHS Foundation Trust, London, UK

michaellunn@nhs.net

**Running title:** COVID-19 vaccination and Guillain-Barré syndrome

**Keywords:** COVID-19 vaccination; Guillain-Barré syndrome
**Abbreviations:** ABN = Association of British Neurologists; AESI = Adverse Event of Special Interest; BPNS = British Peripheral Nerve Society; DHSC = Department of Health and Social Care; GBS = Guillain-Barré syndrome; NHS = National Health Service; NHSE = National Health Service England; NID = National Immunoglobulin Database; NIMS = National Immunisation Management System; VIIT = Vaccine-induced immune thrombotic thrombocytopenia

**Introduction**

The first year of the COVID-19 pandemic produced robust information on the neurological and neuropsychiatric sequelae of SARS-CoV-2 infection. In the peripheral nervous system, brachial neuritis, facial palsy and Guillain-Barré syndrome (GBS) were subjects of particular interest.

From January 2020, case reports and case series of patients with GBS occurring around the time of SARS-CoV-2 infection raised the possibility of a link between GBS and COVID-19. However, a large national study of the UK population as well as in Singapore showed a decreased incidence of GBS and failed to find a definitive link between GBS and COVID-19 infection.

GBS became an adverse event of special interest (AESI) related to vaccination in the 1970s when an excess of GBS cases was detected in the United States during the 1976/1977 A/New Jersey/76 influenza (‘swine flu’) vaccination campaign. Serial epidemiological analyses established the rate of GBS attributable to the ‘swine flu’ vaccine was approximately 4.9-5.9 per million vaccines. Although GBS has been identified in subsequent annual surveillance of influenza vaccination programmes at a rate of 1 to 1.6 per million doses, a pathogenic explanation has not been found. GBS was associated with adenovirus vaccination in a seven-year observational study of 1.3 million of US military personnel. This study reported 12 GBS cases (about 1 per 100,000 exposures), but it is unclear if this represents an increase above the baseline incidence rate; the study has not been replicated and neither plausibility nor causation have been confirmed. The case for other vaccines being associated with GBS is more equivocal. Despite initial reporting concerns of neurological disease associated with the yellow fever attenuated vaccine, an American population study found only 0.5-2 reported GBS cases per million vaccine doses, similar to the population-based incidence of GBS of 1-2/100,000 person-years with seasonal variation noted across populations. Expert consensus is that GBS risk attributable to vaccination is mostly present up to 6 weeks (42 days).

The global rollout of COVID-19 vaccines triggered extensive monitoring, with GBS as an AESI. Very rare adverse events, not visible even in large clinical trials, can be identified when mass vaccination
monitoring systems are in place, and particularly when a unique disease phenotype emerges. Vaccine-induced immune thrombotic thrombocytopenia (VIIT)\textsuperscript{11} and more recently myocarditis\textsuperscript{12} were identified this way. VIIT occurs most commonly in association with ChAdOx1 nCoV-19 (AstraZeneca) recombinant adenoviral vector vaccine. VIIT manifests as thromboses, including cerebral venous sinus thrombosis, with an estimated incidence of 1 case per 100,000 exposures.\textsuperscript{11} Myocarditis seems specific to the tozinameran (Pfizer) and mRNA-1273 (Moderna) vaccines.\textsuperscript{12}

Non-replicating viral vectors can deliver vaccination antigen to the host. Adenoviruses are commonly used, and four current adenoviral vector COVID-19 vaccines are authorised in at least one country (AstraZeneca, Sputnik V, Janssen and Convidecia). Despite the single observational study of McNeil \textit{et al.}\textsuperscript{9} adenovirus vectors are thought to be benign. ChAdOx1 nCoV-19 utilises a replication-deficient simian adenovirus vector designed to evade anti-human adenovirus neutralising antibodies to stimulate a robust immune response.

The UK COVID-19 vaccination programme began on the 8\textsuperscript{th} December 2020 with tozinameran, then ChAdOx1 nCoV-19 (AstraZeneca) in January and subsequently mRNA-1273 vaccinations. Vaccination was delivered sequentially to cohorts of the most vulnerable and elderly followed by deciles of age. 50\% of adults over 50 years of age had had their first vaccination by mid-February 2021.

We aimed to combine multiple national data sources and systematically investigate any relationship between COVID-19 vaccination and excess cases of GBS during the UK COVID-19 vaccination programme. We retrospectively interrogated a large database of patients hospitalised with GBS in England, Scotland and Northern Ireland treated with immunoglobulin from the National Immunoglobulin Database (NID). Using the common NHS identifier, we combined the English data with data from the National Immunisation Management System (NIMS) on all COVID-19 vaccinations data in England. Separately, we characterised a large surveillance dataset of the incident UK GBS cases, presenting both after COVID-19 vaccination, and also without vaccination during the same period, recording the timing of onset after COVID-19 vaccination.

Materials and methods

Retrospective analyses of NID/NIMS datasets

All cases of GBS admitted to hospital in England, Scotland and Northern Ireland and considered for immunoglobulin treatment are recorded in the NID. Because NHS England (NHSE) procures the total
immunoglobulin supply for the UK except Wales, and mandates that all immunoglobulin
prescriptions are approved by the local clinical panel and reported onto the Immunoglobulin
Database within 90 days of administration to facilitate repayment of immunoglobulin costs to the
trusts, there is nearly 100% compliance with detailed recording of immunoglobulin use across the
three UK regions. All cases are confirmed as GBS by the admitting clinician and reviewed and
authorised by an independent Immunoglobulin Assessment Panel, although Brighton Criteria are not
recorded.

We extracted NID GBS cases from 1 January to 31 October 2021 and recorded diagnosis, their
unique identifier and date of first immunoglobulin prescription. These numbers were compared to
the historical GBS cases recorded in the NID from 2016 to 2020.

UK Department of Health and Social Care (DHSC) guidance for GBS treatment recommends
intravenous immunoglobulin (IVig) as first line therapy for patients with Hughes Grade 4 or more
(significant disability), disease progressing towards intubation or ventilation or with high probability
of respiratory insufficiency (mEGRIS score ≥3) or predicted poor prognosis (mEGOS ≥4). Although
plasma exchange (PLEX) is also considered a first line option, in practice, this is not readily available
and is very seldom used. Utilising IVig use as a proxy for GBS incidence under-estimates the true
incidence of GBS, as milder cases are not treated. However, IVig is estimated to be given to 86% of
European and UK GBS cases, and the 2021 data can be compared to previous years with similar
clinical behaviours for admitted patients.

The National Immunisation Management System (NIMS) database is a national point of care system
for capturing vaccination data from England. Patients in the NIMS database are also registered with
their NHS number. The COVID-19 vaccination data were linked to the English cases of GBS identified
from the NID from 8 December 2020 to 8 July 2021 using the unique NHS identifier by NHS England.
The start date was the commencement of the COVID-19 vaccination programme in the UK, Of note,
the NIMS database captures information on vaccinations for England only; Scottish and Northern
Irish GBS data were not included in this section of the analysis. At the time of analysis, data on
immunoglobulin administration for GBS were available to mid-July 2021. To accommodate the need
for a 6-week post-vaccination follow-up information on vaccinations up to and including 27 May
2021 was included. The exposed population, which was used to calculate GBS rates post-vaccination,
was taken from weekly published cumulative counts of vaccine usage in England up to this date.
Prospective surveillance study

We conducted a prospective surveillance study to compare the demographic and phenotypic characteristics of GBS cases reported from 1 January 2021 to 7 November 2021, comparing GBS cases reported as having received COVID-19 vaccination and cases without vaccination. We recognise the included cases are heavily influenced by reporting bias as there was significant interest in the possibility of vaccination-related GBS at the time. The surveillance study should not be used in direct comparison to the retrospective analyses of linked data described above.

Reports of GBS were submitted by members of the British Peripheral Nerve Society (BPNS) and the Association of British Neurologists (ABN), with regular reminders to collect information on hospital presentations of GBS during the study period. Data were entered into the International Neuromuscular COVID-19 database ([https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/news/2020/may/international-neuromuscular-covid-19-database](https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/news/2020/may/international-neuromuscular-covid-19-database)), at the Centre for Neuromuscular Disease, where database questions had been adapted to allow for reporting of COVID-19 vaccine-related neuromuscular cases. Surveillance study data collection ended on 7 November 2021 to allow time for retrospective case reporting. Anonymised clinical data of demographics, GBS diagnostic criteria, vaccine details, and prior COVID-19 infection, symptoms and management were collected. Cases were classified according to Brighton Collaboration GBS Working Group criteria⁶ by the study team to describe level of diagnostic certainty were recorded as previously.⁴

Two cases were excluded from analysis as the reporting clinicians later informed us of a change in diagnosis.

Statistical Analysis

Statistical analysis was performed using STATA 16¹⁷ and R v4.0.2/ v4.0.3 (R Core Team).¹⁸

An ecological analysis presenting the number of GBS cases identified in the NID by calendar month was used to compare the incidence of GBS in the UK across the years 2016-2020 with that seen in January-July 2021.

The Spearman’s rank correlation test was used to test for correlation between the time after the first vaccine dose and the incidence of GBS.

One-way ANOVA was used to compare yearly GBS rates within age deciles of the linked NID/NIMS data in 2021 compared to 2019 and 2020, to determine if age distribution of GBS differed compared
to previous years, using ONS population estimates as the denominators for calculation of rates. As GBS numbers were only available until July 2021, an estimate of annual numbers was produced on the assumption of a stable GBS incidence through the year to enable comparison to prior years. ONS population estimates for 2021 were assumed to be the same as 2020.

For the prospective surveillance study, Chi-square and Kruskal-Wallis tests were used to test for correlations between patient demographics, GBS characteristics or treatment details, and exposure to COVID-19 vaccination within 6 weeks of GBS onset.

A significance value of $p<0.05$ was used throughout.

**Ethics**

The UK Health Research Authority was consulted and advised that the study did not require review by an NHS Research Ethics Committee, as this was an analysis of previously collected, non-identifiable anonymised data.

**Data availability**

Data are available on request to the corresponding author.
Results

Retrospective analyses of NID/NIMS datasets

Ecological analysis – GBS cases recorded in NID from 2016 to 2020

Between 2016 and 2020, the NID recorded an average of 1283 immunoglobulin-treated cases of GBS per year (range 1053-1409, average 107 cases per month). As described, this represents the vast majority of hospitalised GBS cases in England, Scotland and Northern Ireland, resulting in an estimated GBS incidence of 1.57-2.1 per 100,000 individuals per year. This is comparable to previous European and North American studies with incidence rates of between 0.84-1.91 per 100,000 individuals per year. As previously described, the UK experienced an overall reduction in cases in 2020 during the height of the COVID-19 pandemic, resulting in the lowest case number and estimated incidence in the five-year period.

Fig. 1 summarises monthly absolute incidence of GBS in the England, Scotland and Northern Ireland from the years of 2016 to 2020, and compares these to the monthly figures of GBS incidence from January to October 2021 during the UK vaccination programme. A total of 996 GBS cases were recorded from January to October 2021, a lower total than the months January-October 2016 to 2019 (range 1054-1182) but higher than for January-October 2020 (856).

The number of GBS cases in January 2021 was significantly lower than the mean number seen in the same month 2016-2020, continuing the trend of lower GBS rates from 2020. However, England, Scotland and Northern Ireland experienced a spike of GBS cases in March and April 2021, before rates fell again below the lower range of the 95% CI of the 2016-2020 average in July to October 2021.

Analyses of linked NID/NIMS data

Annual GBS cases in England between 2019 and July 2021 were stratified by age decile, enabling age-specific incidence to be compared to recent years (Table 2). To enable a comparison across years, an estimate of annual numbers for 2021 was produced based on assumption of a stable GBS incidence through the year. An excess of cases in the 50-59 and 60-69 age groups was identified compared to 2019 and 2020, with statistically significant differences between age groups (p=0.00033).
Using the linked NID/NIMS data, the first record of GBS occurring within 6 weeks after a COVID-19 vaccination was in January 2021. Of note, not all GBS patients in NID had a vaccination record. 198 cases of GBS identified in the linked NID/NIMS data study period occurred within 6 weeks of the first dose of any COVID-19 vaccine (0.618 cases per 100,000 vaccinations in 6 weeks, all ages). A total of 32.1 million first dose vaccinations were recorded during the reporting period (20.3 million ChAdOx1 nCoV-19, 11.5 million tozinamerican and 0.3 million mRNA-1273). Of the 198 linked GBS cases, 176 followed a first dose ChAdOx1 nCoV-19 vaccine (rate 0.868 per 100,000) and 21 followed a first dose tozinamerican vaccine (rate 0.183 per 100,000). Only one case was reported within 6 weeks of mRNA-1273 vaccination. Only 23 GBS cases were reported within 6 weeks of any second vaccine dose.

Table 1 and Fig. 2 summarise patient characteristics of GBS cases in England occurring within 6 weeks of first COVID-19 vaccination. The GBS incidence after first vaccination was highest in males receiving the ChAdOx1 nCoV-19 vaccine (1.069 per 100,000 doses).

The number of GBS cases following first and second dose COVID-19 vaccination, with an onset at any day up to 84 days after vaccination was plotted (Fig. 3). A peak of GBS cases is observed around 24 days following a first dose, with higher numbers of cases seen 2-4 weeks post vaccination than in other periods. First doses of ChAdOx1 nCoV-19 vaccine account for the majority of this increase. A similar pattern is not seen following a second dose of any vaccine. Using the Spearman’s rank correlation test of randomness, the occurrence of GBS was random for all times after the first-dose tozinamerican vaccine (p=0.84) (no peak associated with tozinamerican vaccine) and after the second-dose vaccination of all vaccines (p=0.85). However, it was non-random for ‘all first-dose’ vaccination (p=0.009) and the first dose of the ChAdOx1 nCoV-19 vaccination (p=0.004).

Using case numbers from day 43-84 after first-dose vaccination as a comparison group (assuming this group represents a baseline random GBS rate), the excess risk in the first 42 days post- ChAdOx1 nCoV-19 vaccine is 0.576 GBS cases per 100,000 doses (95% CI 0.481-0.691). With an estimated 20.3 million first ChAdOx1 nCoV-19 doses given at the time of analysis, this suggests an absolute number of 98-140 excess GBS cases. There was no significant difference between the GBS cases associated with the first dose of tozinamerican and second-dose vaccination numbers in the day 0-42 or day 43-84 case numbers. Fig. 4 summarises the estimated excess risk for different vaccinated groups.

**Prospective surveillance study**

Between 1 January and 7 November 2021, 121 cases of GBS were reported by the BPNS/ABN network. Since clinicians and the public were highly sensitised to vaccination and concerns about risk, the reporting of this dataset is biased in favour of vaccine-related cases. The median age of
reported cases was 59 years, with 59% being male. 106 patients (87.3%) had received COVID-19 vaccination prior to GBS onset, with 80 (66.1% of the total dataset) having received a first-dose vaccination within 42 days of GBS onset. In comparison, from the linked NID/NIMS dataset, 198 of the 659 GBS cases in England during this timeframe (30%) were reported to be within 42 days of vaccination. This highlights the reporting bias of the dataset towards vaccine-associated GBS. As expected with the timing of the vaccine rollout, 90% of GBS cases reported from January – April 2021 were within 6 weeks of vaccination, compared to only 35% of cases from May 2021 onwards.

Further demographic and clinical characteristics of the patients described within the dataset are shown in Table 3.

Forty-two patients (34.7%) were reported to have facial weakness in association with other GBS findings. Facial weakness was bilateral in 37 of these patients. Only 7 patients (5.8%) had pure bilateral facial paralysis with paraesthesia.

A single patient was reported to have a recurrent GBS-like illness following second-dose vaccination. After the first dose of ChAdOx1 nCoV-19 vaccine the patient initially developed a facial diplegia and paraesthesia phenotype with subsequent gait disturbance and elevated CSF protein, and improved with IVlg. Two months later, two weeks after their second dose of ChAdOx1 nCoV-19 vaccination, they developed increasing weakness with neuropathic pain, with elevated CSF protein, demyelinating changes on nerve conduction studies and MRI enhancement of the cauda equina, with only partial response to IVlg treatment.

Only four patients were reported with positive ganglioside antibodies (GM1, GM2, GM1/GD1b, GD1a/GD1b), but this was likely to have been under-reported because of the time delays in anti-ganglioside results being available and inconsistent testing. Equally, limited COVID access to neurophysiology services may explain why only 84 of the 121 patients had nerve conduction studies; these data deficiencies limit the Brighton Collaboration diagnostic categorisation.

Comparing surveillance study patients who had first-dose vaccination within 42 days of GBS onset to unvaccinated patients and patients who had GBS more than 42 days after first-dose vaccination, no significant differences were found in terms of gender \((p=0.54)\), age \((p=0.25)\), highest level of care \((p=0.36)\), Hughes GBS disability score on admission \((p=0.75)\), Brighton level of diagnostic certainty \((p=0.53)\), nerve conduction study changes \((p=0.44)\), treatment \((p=0.52)\) or presence of unilateral or bilateral facial weakness \((p=0.77)\).
Discussion

We have presented parallel studies designed to investigate a possible relationship between COVID-19 vaccination and GBS. The first used existing linked databases and the second was based on prospective case reporting.

These data suggest a clear and plausible, excess of cases of GBS associated with the first dose of ChAdOx1 nCoV-19 COVID-19 vaccination, occurring in the first 42 days. The complexities of timing and delivery of multiple vaccines to age and at-risk cohorts of patients in the UK, on a naturally unstable baseline make identification and quantification of the risks difficult. However, the data provide an estimate of 5.8 cases of GBS (4.8 – 6.9) per million first doses of ChAdOx1 nCoV-19 vaccine and no measurable excess of GBS associated with first doses of tozinameran. This equates to an absolute excess of between 98 and 140 cases of GBS attributable to ChAdOx1 nCoV-19 vaccination up to 8 July 2021 in England. However, this should be compared to estimates that the vaccination programme has directly averted over 52,600 hospitalisations, between 21.3 and 22.9 million infections and between 57,500 and 62,700 deaths by the same time.\textsuperscript{70}

The total number of cases of GBS in the NID from January to October 2021 is lower than the 10-month total of January to October 2016 to 2019; it is higher than total case numbers compared to 2020. A monthly increase in GBS cases in March and April 2021 was notable, but total numbers fell back into the normal range thereafter and thus this ‘spike’ is the only hint of a causative link in simple occurrence data.

The spike in case numbers and the subsequent return to normal levels might be explained in several ways. The baseline onto which any vaccination-related cases are built varies because of the normal seasonal reduction of GBS, but also the unknown effects of ongoing social distancing measures, which reduced the 2020 cases of GBS by about 1/3. Social distancing and other lockdown measures in the UK were slowly relaxed in the first half of 2021 and some GBS increase might be expected through greater pathogen re-exposure. The remaining social distancing measures practiced may account for the lower than usual numbers of GBS cases in July – October 2021.

A contribution of all COVID-19 vaccination across all ages towards an increased risk for GBS might result in a more sustained rise, especially given that a large number of first-dose COVID-19
vaccinations were administered in the first six months. 9,646,715 people, mostly the older and more vulnerable, were vaccinated from early December 2020 to 1st February. One might thus have expected to see GBS cases from January onwards.

However, from 1 Feb 2021 to 1 May 2021, a further 24,858,665 adults were vaccinated (representing 50.5% of the UK population). ChAdOx1 nCoV-19 vaccinations commenced in early January, quickly overtaking tozinameran as the predominant vaccine administered, to a significant proportion of the apparently more susceptible 50- to 70-year-old age group.

Interestingly, there is no recognisable increase in GBS after the second dose which may be a pathophysiological phenomenon, or because patients experiencing adverse effects from the first dose did not take the second vaccine dose. The single patient in our surveillance study who had recurring neuropathic symptoms after second-dose vaccination appears to be a unique report in the UK at this time, and may potentially represent acute-onset chronic inflammatory demyelinating polyradiculoneuropathy (A-CIDP) rather than true GBS. A recent study from Israel of COVID-19 vaccinations in patients with previous GBS described a single patient with recurrent GBS-like illness time-linked to both doses of their tozinameran vaccination, but limited information is available regarding the strength of GBS diagnosis.

Despite the excess incidence is estimated to be 5.8 cases per million doses, similar to the estimates for the 1976 ‘swine flu’ vaccine and higher (but within the same order of magnitude) as the reported excess cases for the modern influenza and yellow fever vaccines. It is far below the 1:1000 cases of GBS in C. jejuni gastroenteritis or Zika-virus.

The reason for the association between only ChAdOx1 nCoV-19 vaccination alone and GBS is unclear. COVID-19 infection does not have a strong, or possibly any, increased risk of GBS, and the lack of increased risk associated with tozinameran vaccination implies that it is unlikely that the COVID-19 spike protein is the causative factor for the increased risk. The excess incidence is estimated to be 5.8 cases per million doses, similar to the estimates for the 1976 ‘swine flu’ vaccine, and higher (but within the same order of magnitude) as the reported excess cases for the modern influenza and yellow fever vaccines. It is far below the 1:1000 cases of GBS in C. jejuni gastroenteritis or Zika-virus.

A non-specific immune activation in susceptible individuals might therefore be implicated, but if that were the case similar risks might apply to all vaccine types. It is therefore logical to suggest the simian adenovirus vector may account for the increased risk. Adenoviruses have not been strongly
associated with GBS in previous studies, and any association between adenoviral vaccination and GBS has only once been reported. Nevertheless, adenovirus testing is not routinely performed in cases of GBS in the UK, and whether they may account for a proportion of ‘idiopathic’ or ‘serology negative’ GBS may be the subject for further study.

Although the first retrospective analysis presented here employs two cross-referenced national and mandated datasets, there are still confounders, bias and criticisms as applicable to many epidemiological studies. We were unable to assess the robustness of diagnosis of cases of GBS administered immunoglobulin. However, these patients would need to be unwell enough to be admitted to hospital, and the diagnosis was assessed not only by the admitting physicians but also by an Immunoglobulin Assessment Panel who authorised immunoglobulin. Furthermore, the data are controlled against data from earlier years where GBS rates are consistent with other epidemiological studies. We recognise that patients with ‘mild GBS’ may not attend hospital or be treated, but this has been the same in past years. We also recognise that patients may have been more reluctant to attend hospital, although this was not obviously observed in 2021, and paralysed patients are likely to have attended more than those with lesser disability.

We explored detailed phenotypes by collecting data on GBS presentations to UK neurologists with a continuation of the BPNS/ABN surveillance study. 121 cases were reported, representing only 13% of GBS cases in that period of 2021. Clinicians were much more likely to report cases with recent vaccination compared to those who were unvaccinated. Nonetheless, this dataset allowed for deeper confirmation of GBS diagnoses, with 79% of the cohort meeting Brighton Collaboration diagnostic criteria level 1, 2, or 3 (compared to 15% of the cases reported to the MHRA ‘Yellow Card’ system [personal communication]). Within our dataset, there were no differences identified between patients who had recent vaccination and those who had not, in terms of baseline demographics, disease course or treatment. Although BPNS and ABN members reported cases of facial weakness associated with GBS, there was no increase linked to vaccination status. The description of some of these cases best fit the ‘atypical’ GBS presentation of ‘bilateral facial weakness with paraesthesia’, which is felt to represent <5% of total GBS cases.

Another recently published UK-based study has analysed neurological complications in the context of recent COVID-19 vaccination and infection, and has reported an increased risk of GBS with an incidence rate ratio (IRR) of 2.90 at 15-21 days after the ChAdOx1 nCoV-19 vaccine, and 5.25 after a positive COVID-19 test. This equated to an excess GBS incidence of 3.8 per million doses ChAdOx1 nCoV-19 vaccine and 14.5 per million COVID-19 infections. However, neurological manifestations were identified using hospital coding data, which may be less accurate than NID identification of GBS.
cases, given that the latter requires scrutiny by local immunoglobulin panels. This lack of individual review of cases may be seen in their finding that 34 patients were admitted with coding both for Bell’s palsy and GBS after ChAdOx1 nCoV-19 vaccination (22% of their ChAdOx1 nCoV-19-related GBS cohort), rather than analysing these cases as GBS cases with facial weakness. Mortality rate was 1.8% in that cohort, much lower than the 3-10% mortality generally associated with GBS. In addition, 16% of COVID-19-associated GBS in their cohort (7/43 cases) were diagnosed on the same day as COVID-19 diagnosis, which is improbable for a post-infectious immune process, raising queries about the accuracy of the timing of onset. We thus believe that our study’s findings on excess risk are likely to be more accurate.

Another UK study pending publication has described increased likelihood of developing the facial diplegia with paraesthesia GBS variant in association with COVID-19 vaccination, but this assertion is based on a smaller case series than our surveillance study, without a relevant control group.

Our study reports an association between first-dose ChAdOx1 nCoV-19 vaccination and GBS, accounting for an estimated excess incidence of 5.8 per million doses. The cause for this association remains unclear, and excess risk remains comparable to previous vaccine-associated GBS. The risk in proportion to the benefits of vaccination is very small. Further studies are required to confirm these observations, to determine causality, to explore the pathogenic mechanisms and to investigate effects of other COVID-19 vaccine preparations in use elsewhere in the world.

**Acknowledgements**

This section is not mandatory.

**Funding**

No specific funding was received for this work. P.M. Machado, M.P. Lunn and A.S. Carr are supported by the National Institute for Health Research (NIH) University College London Hospitals (UCLH) Biomedical Research Centre (BRC). R.Y.S. Keh is funded by GBS-CiDP Foundation International.
Competing interests

P.M. Machado has received consulting/speaker’s fees from Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript. The remaining authors report no competing interests.

Appendix 1

BPNS/ABN COVID-19 Vaccine GBS Study Group:

Hadi Manji, National Hospital of Neurology and Neurosurgery, Queen Square, University College London Hospitals NHS Foundation Trust, London

Tim Lavin, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester

James B. Lilleker, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester

David Gosal, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester

Robert D.M. Hadden, Kings College Hospital NHS Foundation Trust, London

Taylor Watson-Fargie, Institute of Neurological Sciences, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow.

Kathryn Brennan, Institute of Neurological Sciences, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow.

Andreas Themistocleous, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

Jacquie Deeb, Queens Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford

Ana Romeiro, Wexham Park Hospital, NHS Frimley Health Foundation Trust, Slough

Puja Mehta, Kings College Hospital NHS Foundation Trust, London; UCL Queen Square Institute of Neurology, London
Dimitri Kullmann, National Hospital for Neurology and Neurosurgery, Queen Square, University College London Hospitals NHS Foundation Trust, London

James Miller, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

Stephen Keddie, The Royal London Hospital, Barts Health NHS Trust, London

Amar Elsaddig, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester

Adam Molyneux, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford

Plamen Georgiev, Broomfield Hospital, Mid and South Essex NHS Foundation Trust, Chelmsford

Aaron Ben-Joseph, Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Kent

James Holt, The Walton Centre NHS Foundation Trust, Liverpool

Jacob Roelof, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

Fadi Alkufri, Kent and Canterbury Hospital, East Kent Hospitals University NHS Foundation Trust

David Allen, Southampton General Hospital, University Hospital Southampton NHS Foundation Trust, Southampton

Simon Shields, Somerset NHS Foundation Trust, Somerset

Stephen Murphy, Imperial College Healthcare NHS Trust, London

Harri Sivasthiaaseelan, Homerton University Hospital NHS Foundation Trust, London

Richard Sylvester, Homerton University Hospital NHS Foundation Trust, London

Abdul Al-Saleh, The Royal Wolverhampton NHS Trust, Wolverhampton

Rhys Roberts, Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge

Kannan Nithi, Northampton General Hospital, Northampton General Hospital NHS Trust, Northampton

Lahiru Handdunnethi, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford
Kate Wannop, Kings College Hospital NHS Foundation Trust, London

Amit Batla, Royal Free Hospital NHS Foundation Trust, London

Anna Sadnicka, Royal Free Hospital NHS Foundation Trust, London

Jananee Sivaganasundaram, Epsom and St Helier University Hospitals NHS Trust, Epsom

Tatyana Yermakova, Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Leeds

Ravi Dasari, Kent and Canterbury Hospital, East Kent Hospitals University NHS Foundation Trust

Graziella Quattrocchi, North Middlesex University Hospital NHS Trust, London

Harriet Ball, North Bristol NHS Trust, Bristol

Rebecca Cooper, Princess Royal Hospital, Haywards Heath, University Hospitals Sussex NHS Foundation Trust

Daniel Whittam, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester

Mohanned Mustafa, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester

Gabriel Yiin, Great Western Hospitals NHS Foundation Trust, Swindon

Shayan Ashjaei, Kings College Hospital NHS Foundation Trust, London

Andrew J. Westwood, Tunbridge Wells Hospital, Maidstone and Tunbridge Wells NHS Trust, Kent

Michelle Dsouza, Kent and Canterbury Hospital, East Kent Hospitals University NHS Foundation Trust

Eng Chuan Foo, Calderdale Royal Hospital, Calderdale and Huddersfield NHS Foundation Trust, Halifax

Shwe Zin Tun, Calderdale Royal Hospital, Calderdale and Huddersfield NHS Foundation Trust, Halifax

Khine Khine Lwin, Calderdale Royal Hospital, Calderdale and Huddersfield NHS Foundation Trust, Halifax

Gorande Kanabar, East & North Hertfordshire NHS Trust
References


Figure legends

**Figure 1 NHSE Immunoglobulin Database GBS cases 2016-2021.** NHSE Immunoglobulin Database-derived numbers of GBS cases reported per month between 2016 and 2021 (year to date). The table below summarises GBS case numbers in 2021 to date as well as 95% confidence intervals (CI) for case numbers between 2016-2020. *2021 GBS monthly number lower than 95% confidence interval of 2016–2020 monthly numbers; †2021 GBS monthly number higher than 95% confidence interval of 2016–2020 monthly numbers.

**Figure 2 GBS case rate within 6 weeks of first-dose COVID-19 vaccination in England.** Estimated rate of GBS cases within 6 weeks of first COVID-19 vaccination (per 100,000 doses), separated (a) by vaccine type, (b) by age/gender, (c) by age for ChAdOx1 nCoV-19 and tozinameran vaccines, and (d) by gender for ChAdOx1 nCoV-19 and tozinameran vaccines. Size of dots weighted based on GBS case numbers. Crosses represent upper and lower limits of 95% confidence intervals.

**Figure 3 GBS case numbers in England by day following vaccination.** Number of GBS cases 0 to 84 days following (a) any first dose vaccination, (b) first dose stratified by vaccine brand and (c) second dose COVID-19 vaccination.

**Figure 4 Excess risk in first 42 days following vaccination in England.** Estimated incidence of GBS cases within 6 weeks (per 100,000 vaccine doses), comparing reports of GBS cases 0-42 days (red) and 43-84 (blue) for first-dose vaccines (all vaccines, ChAdOx1 nCoV-19, tozinameran) and second-dose vaccines. Diamonds represent upper and lower limits of 95% confidence intervals. An excess of GBS cases is noted in the first 42 days following first-dose vaccination, accounted for by the ChAdOx1 nCoV-19 vaccine.
Table 1 Patient characteristics of GBS cases documented in England occurring within 6 weeks of first dose COVID-19 vaccination with specific breakdown of gender and age for ChAdOx1 nCoV-19 and Tozinameran recipients.

<table>
<thead>
<tr>
<th>Patient characteristic</th>
<th>Cases</th>
<th>Estimated first dose vaccinations (million)</th>
<th>Estimated 6-week GBS case rate (/100,000 first doses)</th>
<th>95% Confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>76</td>
<td>17.0</td>
<td>0.448</td>
<td>0.358-0.560</td>
</tr>
<tr>
<td>Male</td>
<td>120</td>
<td>15.1</td>
<td>0.795</td>
<td>0.665-0.951</td>
</tr>
<tr>
<td>Age group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-29</td>
<td>7</td>
<td>2.0</td>
<td>0.355</td>
<td>0.172-0.732</td>
</tr>
<tr>
<td>30-39</td>
<td>16</td>
<td>3.9</td>
<td>0.415</td>
<td>0.255-0.674</td>
</tr>
<tr>
<td>40-49</td>
<td>33</td>
<td>5.9</td>
<td>0.557</td>
<td>0.396-0.782</td>
</tr>
<tr>
<td>50-59</td>
<td>54</td>
<td>7.1</td>
<td>0.762</td>
<td>0.584-0.994</td>
</tr>
<tr>
<td>60-69</td>
<td>51</td>
<td>5.7</td>
<td>0.890</td>
<td>0.677-1.170</td>
</tr>
<tr>
<td>70-79</td>
<td>33</td>
<td>4.7</td>
<td>0.699</td>
<td>0.498-0.982</td>
</tr>
<tr>
<td>80+</td>
<td>4</td>
<td>2.8</td>
<td>0.145</td>
<td>0.056-0.372</td>
</tr>
<tr>
<td>Vaccine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ChAdOx1 nCoV-19</td>
<td>176</td>
<td>20.3</td>
<td>0.868</td>
<td>0.749-1.006</td>
</tr>
<tr>
<td>Tozinameran</td>
<td>21</td>
<td>11.5</td>
<td>0.183</td>
<td>0.120-0.280</td>
</tr>
<tr>
<td>mRNA-1273</td>
<td>1</td>
<td>0.3</td>
<td>0.325</td>
<td>0.057-1.844</td>
</tr>
<tr>
<td>ChAdOx1 nCoV-19 only</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>68</td>
<td>10.4</td>
<td>0.656</td>
<td>0.517-0.831</td>
</tr>
<tr>
<td>Male</td>
<td>106</td>
<td>9.9</td>
<td>1.069</td>
<td>0.884-1.293</td>
</tr>
<tr>
<td>Age 18-29</td>
<td>4</td>
<td>1.1</td>
<td>0.380</td>
<td>0.148-0.977</td>
</tr>
<tr>
<td>30-39</td>
<td>16</td>
<td>1.6</td>
<td>0.986</td>
<td>0.607-1.601</td>
</tr>
<tr>
<td>40-49</td>
<td>30</td>
<td>4.4</td>
<td>0.683</td>
<td>0.478-0.975</td>
</tr>
<tr>
<td>50-59</td>
<td>50</td>
<td>5.6</td>
<td>0.899</td>
<td>0.682-1.185</td>
</tr>
<tr>
<td>60-69</td>
<td>48</td>
<td>4.0</td>
<td>1.196</td>
<td>0.902-1.586</td>
</tr>
<tr>
<td>70-79</td>
<td>28</td>
<td>2.8</td>
<td>1.007</td>
<td>0.697-1.455</td>
</tr>
<tr>
<td>80+</td>
<td>0</td>
<td>0.9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tozinameran only</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>7</td>
<td>6.5</td>
<td>0.108</td>
<td>0.052-0.224</td>
</tr>
<tr>
<td>Male</td>
<td>14</td>
<td>5.0</td>
<td>0.280</td>
<td>0.167-0.470</td>
</tr>
<tr>
<td>Age 18-29</td>
<td>3</td>
<td>0.9</td>
<td>0.332</td>
<td>0.113-0.976</td>
</tr>
<tr>
<td>30-39</td>
<td>0</td>
<td>2.1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>40-49</td>
<td>2</td>
<td>1.4</td>
<td>0.147</td>
<td>0.040-0.538</td>
</tr>
<tr>
<td>50-59</td>
<td>4</td>
<td>1.5</td>
<td>0.264</td>
<td>0.103-0.678</td>
</tr>
<tr>
<td>60-69</td>
<td>3</td>
<td>1.7</td>
<td>0.175</td>
<td>0.059-0.514</td>
</tr>
<tr>
<td>70-79</td>
<td>5</td>
<td>1.9</td>
<td>0.258</td>
<td>0.110-0.604</td>
</tr>
<tr>
<td>80+</td>
<td>4</td>
<td>1.9</td>
<td>0.210</td>
<td>0.082-0.539</td>
</tr>
</tbody>
</table>

Note mRNA-1273 recipients were not separately analysed due to only a single case being reported.
<table>
<thead>
<tr>
<th>Age group</th>
<th>Number of cases 2019</th>
<th>Number of cases 2020</th>
<th>Number of cases 2021 January -July</th>
</tr>
</thead>
<tbody>
<tr>
<td>GBS cases</td>
<td>ONS (million)</td>
<td>GBS rate per 100,000 patient years</td>
<td>GBS cases</td>
</tr>
<tr>
<td>18-29</td>
<td>109</td>
<td>8.55</td>
<td>1.28</td>
</tr>
<tr>
<td>30-39</td>
<td>117</td>
<td>7.54</td>
<td>1.55</td>
</tr>
<tr>
<td>40-49</td>
<td>120</td>
<td>7.13</td>
<td>1.68</td>
</tr>
<tr>
<td>50-59</td>
<td>191</td>
<td>7.58</td>
<td>2.52</td>
</tr>
<tr>
<td>60-69</td>
<td>213</td>
<td>5.91</td>
<td>3.60</td>
</tr>
<tr>
<td>70-79</td>
<td>202</td>
<td>4.72</td>
<td>4.28</td>
</tr>
<tr>
<td>80+</td>
<td>98</td>
<td>2.84</td>
<td>3.45</td>
</tr>
</tbody>
</table>

Estimated annual total for 2021 (italics) is extrapolated assuming stable GBS incidence across the year based on numbers from January to July 2021. *For 2021 ONS population estimates were assumed to be the same as 2020. ONS = Office of National Statistics population estimates; GBS rate = incidence rate of GBS cases (per 100,000 patient years, assuming that each individual in the ONS population estimate is followed for a full year, or in the case of 2021 estimates for 7 months).
Table 3 Characteristics of patients from clinician-reported surveillance study.

<table>
<thead>
<tr>
<th>Patient characteristic (n = patients with available data)</th>
<th>Number (% or range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of cases</td>
<td>121</td>
</tr>
<tr>
<td>Median age (n=121)</td>
<td>59 years (17-85)</td>
</tr>
<tr>
<td>Gender (n=121)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>50 (41.3%)</td>
</tr>
<tr>
<td>Male</td>
<td>71 (58.7%)</td>
</tr>
<tr>
<td>Race (n=113)</td>
<td></td>
</tr>
<tr>
<td>White British</td>
<td>102 (90.3%)</td>
</tr>
<tr>
<td>Latin American</td>
<td>1 (0.9%)</td>
</tr>
<tr>
<td>South Asian</td>
<td>5 (4.4%)</td>
</tr>
<tr>
<td>Middle Eastern</td>
<td>2 (1.8%)</td>
</tr>
<tr>
<td>Black</td>
<td>3 (2.7%)</td>
</tr>
<tr>
<td>COVID-19 Vaccination received (n=121)</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>106 (87.6%)</td>
</tr>
<tr>
<td>No</td>
<td>15 (12.4%)</td>
</tr>
<tr>
<td>Vaccine manufacturer (n=102)</td>
<td></td>
</tr>
<tr>
<td>ChAdOx1 nCoV-19</td>
<td>89 (87.3%)</td>
</tr>
<tr>
<td>Tozinameran</td>
<td>13 (12.7%)</td>
</tr>
<tr>
<td>Number of vaccine doses (n=104)</td>
<td></td>
</tr>
<tr>
<td>One dose</td>
<td>88 (84.6%)</td>
</tr>
<tr>
<td>Two doses</td>
<td>16 (15.4%)</td>
</tr>
<tr>
<td>Median time from vaccination to GBS onset (n=97)</td>
<td>17 days (0-297)</td>
</tr>
<tr>
<td>Cases within 42 days of first dose vaccination (n=97)</td>
<td>80 (82.3%)</td>
</tr>
<tr>
<td>Recent or previous COVID-19 infection (n=15)</td>
<td></td>
</tr>
<tr>
<td>COVID-19 diagnosed after GBS onset</td>
<td>5</td>
</tr>
<tr>
<td>COVID-19 prior to GBS</td>
<td>10</td>
</tr>
<tr>
<td>Median time from COVID-19 infection to GBS (n=10)</td>
<td>24 (3-266)</td>
</tr>
<tr>
<td>Highest level of care (n=118)</td>
<td></td>
</tr>
<tr>
<td>Home</td>
<td>11 (9.3%)</td>
</tr>
<tr>
<td>Ward</td>
<td>86 (72.9%)</td>
</tr>
<tr>
<td>High Dependency Unit</td>
<td>8 (6.8%)</td>
</tr>
<tr>
<td>Intensive Care Unit</td>
<td>13 (11.0%)</td>
</tr>
<tr>
<td>Hughes GBS score on first assessment (n=111)</td>
<td></td>
</tr>
<tr>
<td>0 – Normal</td>
<td>6 (5.4%)</td>
</tr>
<tr>
<td>1 – Slight clinical symptoms/signs</td>
<td>8 (7.42%)</td>
</tr>
<tr>
<td>2 – Able to walk 5m unaided, unable to run</td>
<td>32 (28.8%)</td>
</tr>
<tr>
<td>3 – Able to walk 5m with help</td>
<td>24 (21.6%)</td>
</tr>
<tr>
<td>4 – Bedridden/chairbound</td>
<td>38 (34.2%)</td>
</tr>
<tr>
<td>5 – Ventilator-assisted breathing</td>
<td>3 (2.7%)</td>
</tr>
<tr>
<td>Brighton Criteria classification* (n=121)</td>
<td></td>
</tr>
<tr>
<td>Level 1 (highest certainty)</td>
<td>50 (41.3%)</td>
</tr>
<tr>
<td>Level 2</td>
<td>36 (29.8%)</td>
</tr>
<tr>
<td>Level 3</td>
<td>9 (7.4%)</td>
</tr>
</tbody>
</table>
Level 4 (lowest certainty) 26 (21.5%)

Presence of bilateral flaccid limb weakness (n=121) 105 (86.8%)

Decreased or absent deep tendon reflexes in the weak limbs (n=121) 114 (94.2%)

Monophasic pattern with nadir 12 hours to 28 days from onset (n=121) 112 (92.6%)

Lumbar puncture showing albumino-cytological dissociation (n=103) 94 (91.3%)

Nerve conduction studies in keeping with GBS (n=84) 82 (97.6%)

Nerve conduction studies subtype (n=79)
- Axonal 7 (8.9%)
- Conduction block 2 (2.5%)
- Demyelinating 63 (79.7%)
- Equivocal 2 (2.5%)
- Mixed 5 (6.3%)

Other diagnoses still being considered at latest time of reporting (n=118) 3 (2.5%)

Treatment (n=121)
- No treatment 18 (14.9%)
- Intravenous immunoglobulin 90 (74.4%)
- Steroids 5 (4.1%)
- Plasma exchange 5 (4.1%)
- Combination of above 3 (2.5%)

Data are presented either as n (%) or median (range).
UK National immunoglobulin Database data of GBS case numbers per month from 2016 to 2021

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>126.58</td>
<td>114.60</td>
<td>112.35</td>
<td>92.94</td>
<td>91.22</td>
<td>97.75</td>
<td>80.69</td>
<td>77.75</td>
<td>76.97</td>
<td>85.29</td>
<td>91.06</td>
<td>103.79</td>
</tr>
<tr>
<td>2017</td>
<td>162.22</td>
<td>135.40</td>
<td>137.25</td>
<td>124.26</td>
<td>120.78</td>
<td>111.79</td>
<td>98.51</td>
<td>95.85</td>
<td>98.63</td>
<td>104.71</td>
<td>107.34</td>
<td>139.41</td>
</tr>
<tr>
<td>2018</td>
<td>135.40</td>
<td>134.40</td>
<td>132.35</td>
<td>121.26</td>
<td>119.78</td>
<td>110.79</td>
<td>98.51</td>
<td>95.85</td>
<td>98.63</td>
<td>104.71</td>
<td>107.34</td>
<td>139.41</td>
</tr>
<tr>
<td>2019</td>
<td>135.40</td>
<td>134.40</td>
<td>132.35</td>
<td>121.26</td>
<td>119.78</td>
<td>110.79</td>
<td>98.51</td>
<td>95.85</td>
<td>98.63</td>
<td>104.71</td>
<td>107.34</td>
<td>139.41</td>
</tr>
<tr>
<td>2020</td>
<td>135.40</td>
<td>134.40</td>
<td>132.35</td>
<td>121.26</td>
<td>119.78</td>
<td>110.79</td>
<td>98.51</td>
<td>95.85</td>
<td>98.63</td>
<td>104.71</td>
<td>107.34</td>
<td>139.41</td>
</tr>
<tr>
<td>2021</td>
<td>135.40</td>
<td>134.40</td>
<td>132.35</td>
<td>121.26</td>
<td>119.78</td>
<td>110.79</td>
<td>98.51</td>
<td>95.85</td>
<td>98.63</td>
<td>104.71</td>
<td>107.34</td>
<td>139.41</td>
</tr>
</tbody>
</table>

2021 GBS cases to date: 102* 118 165 164 95 92 77 61 61 61 95% CI (2016-2020): 126.58 - 162.22
Number of cases of GBS following first dose of a COVID-19 vaccine

Number of cases of GBS following first dose of a COVID-19 vaccine, by manufacturer

Number of cases of GBS following second dose of a COVID-19 vaccine
Estimated incidence of GBS days 0-42 vs days 43-84 after COVID-19 vaccination